Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy of Prophylactic Entecavir for Hepatitis B Virus-Related Hepatocellular Carcinoma Receiving Transcatheter Arterial Chemoembolization

  • Li, Xing (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-sen University) ;
  • Zhong, Xiang (Department of Medical Oncology, Shenzhen People's Hospital) ;
  • Chen, Zhan-Hong (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-sen University) ;
  • Wang, Tian-Tian (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-sen University) ;
  • Ma, Xiao-Kun (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-sen University) ;
  • Xing, Yan-Fang (Department of Nephrology, the Third Affiliated Hospital of Guangzhou Medical University) ;
  • Wu, Dong-Hao (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-sen University) ;
  • Dong, Min (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-sen University) ;
  • Chen, Jie (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-sen University) ;
  • Ruan, Dan-Yun (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-sen University) ;
  • Lin, Ze-Xiao (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-sen University) ;
  • Wen, Jing-Yun (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-sen University) ;
  • Wei, Li (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-sen University) ;
  • Wu, Xiang-Yuan (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-sen University) ;
  • Lin, Qu (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-sen University)
  • Published : 2016.01.11
Download PDF
⟨ Previous Next ⟩

Abstract

Background and Aims: Hepatitis B virus (HBV) reactivation was reported to be induced by transcatheter arterial chemoembolization (TACE) in HBV-related hepatocellular carcinonma (HCC) patients with a high incidence. The effective strategy to reduce hepatitis flares due to HBV reactivation in this specific group of patients was limited to lamivudine. This retrospective study was aimed to investigate the efficacy of prophylactic entecavir in HCC patients receiving TACE. Methods: A consecutive series of 191 HBV-related HCC patients receiving TACE were analyzed including 44 patients received prophylactic entecavir. Virologic events, defined as an increase in serum HBV DNA level to more than 1 log10 copies/ml higher than nadir the level, and hepatitis flares due to HBV reactivation were the main endpoints. Results: Patients with or without prophylactic were similar in host factors and the majorities of characteristics regarding to tumor factors, HBV status, liver function and LMR. Notably, cycles of TACE were parallel between the groups. Ten (22.7%) patients receiving prophylactic entecavir reached virologic response. The patients receiving prophylactic entecavir presented significantly reduced virologic events (6.8% vs 54.4%, p=0.000) and hepatitis flares due to HBV reactivation (0.0% vs 11.6%, p=0.039) compared with patients without prophylaxis. Kaplan-Meier analysis illustrated that the patients in the entecavir group presented significantly improved virologic events free survival (p=0.000) and hepatitis flare free survival (p=0.017). Female and Eastern Cooperative Oncology Group (ECOG) performance status 2 was the only significant predictors for virological events in patients without prophylactic antiviral. Rescue antiviral therapy did not reduce the incidence of hepatitis flares due to HBV reactivation. Conclusion: Prophylactic entecavir presented promising efficacy in HBV-related cancer patients receiving TACE. Lower performance status and female gender might be the predictors for HBV reactivation in these patients.

Keywords

References

  1. Arzumanyan A, Reis HM, Feitelson MA (2013). Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer, 13, 123-35. https://doi.org/10.1038/nrc3449
  2. Bruix J, Sherman M (2011). Management of hepatocellular carcinoma: an update. Hepatol, 53, 1020-2. https://doi.org/10.1002/hep.24199
  3. Hongthanakorn C, Chotiyaputta W, Oberhelman K, et al (2011). Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos (t)ide analogues in clinical practice. Hepatol, 53, 1854-63. https://doi.org/10.1002/hep.24318
  4. Huang H, Li X, Zhu J, et al (2014). Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA, 312, 2521-30. https://doi.org/10.1001/jama.2014.15704
  5. Jang JW, Choi JY, Bae SH, et al (2004). Transarterial chemolipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol, 41, 427-35. https://doi.org/10.1016/j.jhep.2004.05.014
  6. Jang JW, Choi JY, Bae SH, et al (2006). A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology, 43, 233-40. https://doi.org/10.1002/hep.21024
  7. Jang JW, Kwon JH, You CR, et al (2011). Risk of HBV reactivation according to viral status and treatment intensity in patients with hepatocellular carcinoma. Antivir Ther, 16, 969-77. https://doi.org/10.3851/IMP1840
  8. Kim IK, Kim BG, Kim W, et al (2012). Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virusinfected patients undergoing cytotoxic chemotherapy for malignancy. Antimicrob Agents Chemother, 56, 5511-9. https://doi.org/10.1128/AAC.00821-12
  9. Li X, Lin Q, Dong M, et al (2010). Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma. Leuk Lymphoma, 51, 1678-85. https://doi.org/10.3109/10428194.2010.499486
  10. Li X, Xing YF, Lin Q, et al (2012). The treatment of severe hepatitis B virus reactivation after chemotherapy. Nat Rev Clin Oncol, 9, 350.
  11. Li X, Zhong X, Chen ZH, et al (2014). Hepatitis B virus DNA negativity acts as a favorable prognostic factor in hepatocellular carcinoma patients. Asian Pac J Cancer Prev, 15, 9635-41. https://doi.org/10.7314/APJCP.2014.15.22.9635
  12. Liver EAftSot (2012). EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol, 57, 167-85. https://doi.org/10.1016/j.jhep.2012.02.010
  13. Lok AS, McMahon BJ (2007). Chronic hepatitis B. Hepatol, 45, 507-39. https://doi.org/10.1002/hep.21513
  14. Lok AS, McMahon BJ (2009). Chronic hepatitis B: update 2009. Hepatol, 50, 661-2. https://doi.org/10.1002/hep.23190
  15. McMahon BJ (2009). The natural history of chronic hepatitis B virus infection. Hepatol, 49, 45-55. https://doi.org/10.1002/hep.22898
  16. Nagamatsu H, Itano S, Nagaoka S, et al (2004). Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol, 99, 2369-75. https://doi.org/10.1111/j.1572-0241.2004.40069.x
  17. Park JW, Park KW, Cho SH, et al (2005). Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study. Am J Gastroenterol, 100, 2194-200. https://doi.org/10.1111/j.1572-0241.2005.00232.x
  18. Peng JW, Lin GN, Xiao JJ, et al (2012). Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization therapy. Asia Pac J Clin Oncol, 8, 356-61. https://doi.org/10.1111/j.1743-7563.2012.01534.x
  19. Torres HA, Davila M (2012). Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol, 9, 156-66. https://doi.org/10.1038/nrclinonc.2012.1
  20. Vizzini GB, Luca A, Marino IR (2003). Hepatitis B virus reactivation after a single session of transarterial chemoembolization in patients with hepatocellular carcinoma. Ann Intern Med, 138, 691-2.
  21. Wu XY, Li X, Chen ZH, et al (2013). An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: a pilot study. Tumour Biol, 34, 909-18. https://doi.org/10.1007/s13277-012-0626-6
  22. Yeo W, Chan HL (2013). Hepatitis B virus reactivation associated with anti-neoplastic therapy. J Gastroenterol Hepatol, 28, 31-7. https://doi.org/10.1111/j.1440-1746.2012.07280.x
  23. Zhong S, Yeo W, Schroder C, et al (2004). High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat, 11, 55-9. https://doi.org/10.1046/j.1352-0504.2003.00467.x
  24. Ziakas PD, Karsaliakos P, Mylonakis E (2009). Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica, 94, 998-1005. https://doi.org/10.3324/haematol.2009.005819

Cited by

  1. Changes of HBV DNA After Chemoembolization for Hepatocellular Carcinoma and the Efficacy of Antiviral Treatment vol.61, pp.9, 2016, https://doi.org/10.1007/s10620-016-4167-5
  2. Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma vol.11, pp.10, 2017, https://doi.org/10.1080/17474124.2017.1343665